Charles Schwab Investment Management Inc Fennec Pharmaceuticals Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 55,452 shares of FENC stock, worth $341,584. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,452
Previous 55,452
-0.0%
Holding current value
$341,584
Previous $338,000
18.05%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding FENC
# of Institutions
64Shares Held
14.9MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$25.1 Million0.57% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$14.8 Million27.51% of portfolio
-
Solas Capital Management, LLC Darien, CT1.92MShares$11.8 Million7.68% of portfolio
-
Dg Capital Management, LLC New York, NY1.52MShares$9.38 Million4.41% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$7.31 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $161M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...